Myeloma Minute: IMF Studies Highlighted by Nature

Best of ASH 2016 Teleconference: What Patients and Caregivers Need to Know

Tune in today for the FREE Best of ASH 2016 Teleconference to be broadcast on Thursday, January 12 at 4 PM PT / 7 PM ET. Join Dr. Brian G.M. Durie as he discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community. To join, click HERE.

Nature Reviews Clinical Oncology Year in Review Names Studies by the IMF as "Fresh Perspectives on Treatment and Moments of Clarity"

In the January 10, 2017 issue of Nature Reviews Clinical Oncology, a number of IMF-originated studies were named as “Fresh perspectives on treatment and moments of clarity” in myeloma research. In particular, the article abstract highlights how “data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility.” If you would like to purchase the full article, please contact the publisher HERE.

 

Two Important ASH Abstracts Report on the Prognostic Values of CT and PET Scans for Multiple Myeloma Patients

In this video, Dr. Jens Hillengass (University of Heidelberg-Heidelberg, Germany) shares the findings of a recent imaging study. He explains that conventional skeletal survey, which has been the standard imaging technique for the detection of bone lesions in multiple myeloma for decades, is in fact, not sufficient. According to this recent study, the sensitivity and prognostic value of whole-body computer tomography (WBCT) with or without positron emission tomography (PET/PET-CT) proves to be the more sophisticated technique for detecting lesions in either smoldering multiple myeloma or active myeloma patients. In the same vein, in this video, Dr. Elena Zamagni (Bologna University School of Medicine- Bologna, Italy) explains how another study was able to identify uniform criteria for interpreting PET-CT scans and guidelines for the future use of this imaging for multiple myeloma patients.

 

In the Seattle Area? Register NOW for a FREE IMF-Hosted Regional Community Workshop

The IMF will host a Regional Community Workshop in Seattle, Washington at the Sheraton Seattle Hotel-Cirrus Ballroom (1400 6th Ave. – Downtown Seattle) from 9 AM PT–3 PM PT on Saturday, February 25, 2017. Myeloma experts, including Drs. Edward Libby (Seattle Cancer Alliance) and Bill Bensinger (Swedish Hospital-Seattle) will be at the event to speak to and interact with attendees. Registration is FREE, but seating is limited. To register now, click HERE.

 

 


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb